Cite
MLA Citation
PJ Mease et al.. “SAT0470 Secukinumab provides sustained improvements in the signs and symptoms of active psoriatic arthritis: 3-year efficacy and safety results from phase 3 future 1 trial.” Annals of the rheumatic diseases, vol. 76, n.d., pp. 952–953. http://access.bl.uk/ark:/81055/vdc_100135139165.0x00005c